Should You Continue to Retain PAHC Stock in Your Portfolio?

Phibro Animal Health Corporation PAHC is well-positioned for growth in the coming quarters, as its Animal Health business continues to gain momentum, bolstered by the addition of Zoetis’ medicated feed additive (MFA) portfolio. Its established operations and broad sales, marketing and distribution network give the company room to expand internationally. A strong financial position adds to the stock’s appeal. However, macroeconomic challenges and near-term uncertainty surrounding Brazil’s antimicrobial transition could weigh on Phibro’s financial results.

Over the past year, this Zacks Rank #3 (Hold) stock has risen 11.3% against the industry’s 25.2% fall and the S&P 500 composite’s 23.4% growth.

The renowned animal health and mineral nutrition company has a market capitalization of $1.40 billion. PAHC has an earnings yield of 9.6% compared with the industry’s yield of 2.6%. PAHC surpassed earnings estimates in each of the trailing four quarters, the average surprise being 16.2%.

Let’s delve deeper.

Tailwinds Supporting PAHC Stock

Animal Health Business Growth Continues: Phibro’s animal health products, including MFAs, vaccines and nutritional specialty products, support animal nutrition and help manage disease outbreaks across major food animal species. The company’s leading MFA portfolio was further bolstered by the integration of Zoetis’ MFA business, which added more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.

In the third quarter of fiscal 2026, Animal Health net sales increased 13% year over year, reflecting growth across MFAs, nutritional specialties and vaccines. The acquired MFA business generated a full quarter of revenues, up 25% versus last year, while legacy MFA sales increased 5% on demand in North America and certain antimicrobials sold by the ethanol performance business. Nutritional Specialty saw higher demand in North America and higher companion animal sales, while vaccine sales growth was driven by higher sales demand in Israel and higher sales of autogenous vaccines.

Image Source: Zacks Investment Research

Potential in Emerging Markets: The company’s global footprint extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries, and South Africa and other countries in Africa. The current strategy remains focused on regions where livestock production is consolidated in large commercial farms, which supports product adoption and recurring demand. In third-quarter fiscal 2026, net sales in Europe, the Middle East and Africa increased 14% year over year, while Asia Pacific sales rose 9%. Latin America and Canada sales jumped 7%, reflecting continued demand across the region. This geographic balance helps offset uneven species cycles and supports management’s expectation for fiscal 2026 net sales growth.

Stable Solvency Structure: Phibro continues to prioritize returning capital through dividends while managing leverage. At the end of third-quarter fiscal 2026, cash and short-term investments were $77.5 million. Total debt was $740.9 million, implying a 3.1 gross leverage ratio and a 2.8 net leverage ratio. Subsequent to the quarter-end, Phibro increased revolving credit commitments by $125 million to $435 million, strengthening liquidity. During the third quarter, the company paid a quarterly dividend of $0.12 per share, or $4.9 million in aggregate.

What Ails Phibro?

Macroeconomic and Trade Policy Risks Remain: Phibro operates in markets exposed to sanctions, bans and broader military conflicts, including the ongoing Russia-Ukraine war. Changes in U.S. trade policy, tariffs and trade agreements could also disrupt its supply chain and raise the cost of key materials. The company has built inventory ahead of tariffs and to meet higher customer demand, which has reduced cash generation and increased working capital needs. Phibro is pursuing the potential recovery of certain U.S. tariffs already paid, but the timing and amount of any refund remain uncertain, and no benefit has been recorded.

Brazil’s Antimicrobial Transition Creates Near-Term Uncertainty: After the fiscal third-quarter end, Brazil implemented a new regulatory framework that removes growth promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin, with a 180-day transition period. Management is working with regulators and industry to ensure a smooth transition and maintain customer supply. However, the timing of therapeutic approvals and the shift to prescription-based demand remain uncertain. With $26 million in fiscal 2025 sales and above-average margins, virginiamycin disruptions in Brazil could weigh on profitability.

PAHC Stock Estimate Trend

The Zacks Consensus Estimate for Phibro’s fiscal 2026 earnings per share (EPS) projects 47.4% growth to $3.08. The estimate has remained constant in the past 30 days. 

The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.49 billion. This suggests a 14.8% rise from the year-ago reported number.

Key Picks

Some better-ranked stocks in the broader medical space are Globus Medical GMED, Veracyte VCYT and Teleflex TFX.

Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 42.3% against the industry’s 6.3% fall over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% compared to the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 5% against the industry’s 6.2% decline over the past year.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research